New stock news | First Journey Biotech will submit a secondary listing application to the Hong Kong Stock Exchange.
According to the disclosure by the Hong Kong Stock Exchange on March 23, Hangzhou Xianwoda Biotechnology Co., Ltd.-B (referred to as Xianwoda Biotechnology) submitted an application for listing on the main board of the Hong Kong Stock Exchange. Morgan Stanley and Zhongjin Company are its joint sponsors.
According to the disclosure on March 23 by the Hong Kong Stock Exchange, Hangzhou Xianwoda Biotechnology Co., Ltd.-B (referred to as Xianwoda Biotechnology) has submitted its listing application to the Hong Kong Stock Exchange Main Board, with Morgan Stanley and CICC as its joint sponsors. This is the second time the company has submitted an application to the Hong Kong Stock Exchange. According to the prospectus, the company was founded in 2017 and has been focusing on the research and development of advanced weight management therapies (mainly for obesity and related diseases). As at the latest practicable date (March 15, 2026), the company has (i) a core product, the preferred GLP-1 exenatide injection (XW003); and (ii) seven other pipeline products.
Related Articles
EBROKER GROUP (08036) announced its annual performance, with a net loss attributable to shareholders of HKD 3.726 million, an increase of 37.24% year-on-year.
JIande International (00865) expects a shareholders' deficit of approximately 6 to 8 million yuan in 2025.
BUTONG GROUP (06090): The trustee purchased a total of 69,700 shares under the stock incentive plan.
EBROKER GROUP (08036) announced its annual performance, with a net loss attributable to shareholders of HKD 3.726 million, an increase of 37.24% year-on-year.
JIande International (00865) expects a shareholders' deficit of approximately 6 to 8 million yuan in 2025.
BUTONG GROUP (06090): The trustee purchased a total of 69,700 shares under the stock incentive plan.
